gyrAMutations in Fluoroquinolone-resistantClostridium difficilePCR-027
Open Access
- 1 March 2007
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 13 (3) , 504-505
- https://doi.org/10.3201/eid1303.060771
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficileJournal of Antimicrobial Chemotherapy, 2006
- Emergence of Clostridium difficile-associated disease in North America and EuropeClinical Microbiology & Infection, 2006
- Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and EuropeThe Lancet, 2005
- Clindamycin, Cephalosporins, Fluoroquinolones, andClostridium difficile–Associated Diarrhea: This Is an Antimicrobial Resistance ProblemClinical Infectious Diseases, 2004
- gyrA and gyrB Mutations Are Implicated in Cross-Resistance to Ciprofloxacin and Moxifloxacin in Clostridium difficileAntimicrobial Agents and Chemotherapy, 2002
- Clostridium difficileGastroenterology Clinics of North America, 2001
- Resistance to Moxifloxacin in Toxigenic Clostridium difficile Isolates Is Associated with Mutations in gyrAAntimicrobial Agents and Chemotherapy, 2001
- In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolatesJournal of Antimicrobial Chemotherapy, 2000
- Epidemics of Diarrhea Caused by a Clindamycin-Resistant Strain ofClostridium difficilein Four HospitalsNew England Journal of Medicine, 1999
- Mechanisms of fluoroquinolone resistanceDrug Resistance Updates, 1999